According to previous studies, anti-malaria drugs were known as chlorquines repurposed to treat cancer for decades, but so far no…
According to previous studies, anti-malaria drugs were known as chlorquines repurposed to treat cancer for decades, but so far no one knew exactly what the chlororines targeted when they attacked a tumor. Now researchers from the University of Pennsylvania declared that an enzyme called PPT1 – opens a new pathway for potential cancer treatments. The results were found in the Journal of Cancer Discovery. The team also used CRISPR / Cas9 redirection to remove PPT1 from cancer cells in the lab and found that elimination of it reduces tumor growth. They describe a potent chlorokin, known as DC661, which can benefit from this new treatment route.
“The discovery of this goal is crucial to the fact that chlorochines are currently being evaluated in clinical trials worldwide, and this knowledge basically changes how we look at these attempts,” says co-author Ravi K. Amaravadi.
is a enzyme that helps control both the mechanical target of rapamycin (mTOR), an important regulator for growth in cancer cells, as well as a process called autophagy, a built-in resistance mechanism that allows cells to survive in attacks by breaking down unnecessary parts and reusing them for to keep alive.
In a previous study, Penn researchers showed that these two processes worked hand in hand, as autophagy provides nutrients that allow mTOR to control growth, while mTOR turns off autofag when nutrients are not needed.
Construction of his previous work used researchers CRI SPR / Cas9 to knockout PPT1 from cancer cells f r to see if its removal had the same effect as chloroquine.
Researchers further showed that the concept of targeting melanoma cells with DC661, which specifically targets PPT1 and produces cell death in many cell lines, is tested both in vitro and in vivo. It is a dimeric form of the antimalarial drug chemistry, which means that it has two molecules of quinacrin bound together with a particular linker.
Amaravadi added that when you put the pieces together, it shows incredible promise.
“We now have a specific molecular target in cancer, as well as a potential way of achieving it,” said Amaravadi. “It not only provides a new context for current clinical trials involving hydroxyclorokine but also the further development of these compounds against clinical Drug candidates open the door for key testing of our compounds or their optimized derivatives versus current kloroquins to see which one is more effective. “
(This story has not been edited by NDTV staff and is automatically generated from a syndicated stream.)